INRLF (Valneva SE) Long-Term Debt: $189.7 Mil (As of Mar. 2026)


INRLF Valneva SE INRLF
55 GF Score
Price $2.62
GF Value $2.69
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Long-Term Debt?

Valneva SE INRLF 55 Long-Term Debt is $189.7 Mil as of Mar. 2026. GuruFocus rates INRLF with a GF Score™ of 55/100 and a GF Value™ of $2.69 (Fairly Valued). The stock has 6 warning signs investors should review.

Valneva SE's Long-Term Debt for the quarter that ended in Mar. 2026 was $189.7 Mil.

Valneva SE's quarterly Long-Term Debt increased from Sep. 2025 ($127.8 Mil) to Dec. 2025 ($188.8 Mil) and increased from Dec. 2025 ($188.8 Mil) to Mar. 2026 ($189.7 Mil).

Valneva SE's annual Long-Term Debt increased from Dec. 2023 ($144.8 Mil) to Dec. 2024 ($174.4 Mil) and increased from Dec. 2024 ($174.4 Mil) to Dec. 2025 ($188.8 Mil).

Valneva SE  (OTCPK:INRLF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Valneva SE Long-Term Debt Related Terms

Valneva SE Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Valneva SE's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE Long-Term Debt Chart

Valneva SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.32 92.40 144.79 174.37 188.83

Valneva SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 174.57 141.13 127.80 188.83 189.67
INRLF
55GF Score
Valneva SE INRLF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $189.7 Mil mean?
Valneva SE (INRLF) has a Long-Term Debt of $189.7 Mil as of Mar. 2026.
Is Valneva SE's Long-Term Debt too high?
Valneva SE's current Long-Term Debt is $189.7 Mil. Overall, Valneva SE has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Long-Term Debt compare to VRTX and REGN?
Valneva SE's Long-Term Debt of $189.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Valneva SE's current Long-Term Debt is $189.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.69, compared to a current price of $2.62 — trading 2.6% below its estimated fair value. The current Long-Term Debt is $189.7 Mil. Valneva SE's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Valneva SE (INRLF), the current Long-Term Debt is $189.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 2.6% below its estimated GF Value™ of $2.69. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Long-Term Debt: $189.7 Mil
  • GF Value™: $2.69 vs. price of $2.62 (2.6% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
55GF Score

Get the complete analysis for INRLF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.69
GF Value